// App-Quantinova.ai

OC 27.4 : Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A – results from A-SURE, a 24-month prospective, non-interventional study

Researchers

Presenter

  • J. Oldenburg

Principal Investigators

  • C. Hay

  • F. Peyvandi

  • A. Tagliaferri

  • P. Holme

  • C. Biron-Andrani

  • H. Malmstrm

  • S. Lethagen

Medical Centers

  • University Clinic Bonn, Bonn, Nordrhein-Westfalen, Germany

  • Department of Laboratory Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

  • Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano, Department of Pathophysiology and Transplantation, and Fondazione Luigi Villa, Milan, Italy

  • Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy

  • 1Department of Haematology, Oslo University Hospital 2Research Institute of Internal Medicine, Oslo University Hospital 3Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Oslo, Norway

  • Hospital Universitario La Paz, Madrid, Spain

  • Haemophilia Treatment Centre, Department of Biological Haematology, University Hospital Montpellier, Montpellier, Languedoc-Roussillon, France

  • Swedish Orphan Biovitrum AB, Stockholm, Stockholms Lan, Sweden

Locations

  • Germany

  • United Kingdom

  • Italy

  • Norway

  • Spain

  • France

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

Disease

  • Hemophilia

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • Recombinant Factor VIII

  • FVIIIFc

  • FVIII

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • NCT02976753

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved